Bluejay Diagnostics (BJDX) EBITDA (2020 - 2026)

Bluejay Diagnostics' EBITDA history runs 7 years deep, the most recent figure standing at -$1.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 2.64% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$7.0 million (down 5.62% YoY), while the FY2025 annual figure was -$7.0 million, up 3.02% from the prior year.
• EBITDA came in at -$1.9 million for Q1 2026 at Bluejay Diagnostics, down from -$1.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.4 million in Q3 2024 to a low of -$2.9 million in Q2 2023.
• A 5-year average of -$2.1 million and a median of -$2.0 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 786.91% in 2022 and surged 41.84% in 2024, its largest moves.
• Bluejay Diagnostics' EBITDA stood at -$2.5 million in 2022, then advanced by 2.73% to -$2.4 million in 2023, then surged by 37.8% to -$1.5 million in 2024, then rose by 1.54% to -$1.5 million in 2025, then slumped by 32.64% to -$1.9 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$1.9 million, -$1.5 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison